Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

2.35
Delayed Data
As of 12:48pm ET
 -0.011 / -0.47%
Today’s Change
2.00
Today|||52-Week Range
7.15
-2.12%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$30.6M

Company Description

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. It distributes products through the following brands: Treximet, Silenor, and Zohydro ER with BeadTek. The company was founded in 1996 and is headquartered in Morristown, NJ.

Contact Information

Pernix Therapeutics Holdings, Inc.
10 North Park Place
Morristown New Jersey 07960
P:(800) 793-2145
Investor Relations:

Employees

Shareholders

Mutual fund holders4.06%
Individual stakeholders2.05%
Other institutional11.22%

Top Executives

John A. SedorChairman & Chief Executive Officer
Angus SmithSenior VP, Chief Financial & Business Officer
Kenneth R. PiñaSecretary, Chief Legal & Compliance Officer, SVP
George P. JonesVice President-Sales & Marketing
Glenn WhaleyPrincipal Accounting Officer & VP-Finance